Breast Cancer Research and Treatment **35**: 299, 1995.
© 1995 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 35

Aldrich TE 51,61
Alhadeff JA 211
Altpeter M 7
Avril A 283

Belotti D 195
Bonichon F 283
Braeuning MP 31
Brandberg Y 267
Bucci L 243
Bufalino R 195

Cance WG 105
Caponigro F 243
Cascinelli N 195
Charreau EH 173
Ciardiello F 293
Clark GJ 133
Coindre J-M 283
Colletta G 293
Colnaghi MI 195
Comella G 147
Comella P 147
Conway K 97
Coronel EC 211
Cremone L 147

Dawson TL 115
de Mascarel I 283
Della Volpe N 147
Der CJ 133
DeVoto E 79
Di Martino N 243
Dran G 173
Dressler L 61
Durand M 283

Earishi M 163
Earp HS 115
Earp JA 7
Edmiston S 97
Eng E 23

Facchini G 243
Fei L 243
Frasci G 147
Fried DB 97
Frisell J 267
Fuqua SAW 233

García de Veas R 187
Garrett PA 97
Geradts J 51,61
Godley PA 91
Graham M 61

Harris AL 293
Heffelfinger S 277
Hulka BS 97

Iaffaioli RV 243
Ikejiri K 221
Imbriani A 147
Inoue H 157

Kaluzny AD 43
Kamamura Y 157
Kawashima H 163
Keshgegian AA 201
Kim N 293
Kitamura K 221
Kiyomatsu K 221
Klabunde CN 43
Komaki K 157
Kuwano H 221

Lanari C 173
Lange MK 211
Laury-Kleintop LD 211
Li X 115
Lidbrink E 267
Liu ET 1,39,51,97,105
Longo S 211
Lower EE 277
Lozano J 187
Luthy IA 173

Mantovani G 243
Martignone S 195
Mayne L 7
Medina MA 187
Ménard S 195
Michigishi T 163
Miller MA 277
Millikan R 51,61,79
Minami M 163
Miyazaki I 163
Mizukami Y 163
Molinolo AA 173
Monden Y 157
Montecchia F 173
Moorman PG 51,61
Morata P 187
Morimoto T 157
Murray R 249
Murrell TGC 225

Nakamura S 163
Newman B 51,61,79
Nishijima H 163
Noguchi M 163
Nonomura A 163
Normanno N 293

O'Malley MS 7
Ohmine Y 157

Pasqualini CD 173
Pellegrini R 195
Persico G 147
Pisano ED 31
Pitt P 249
Plowman G 293

Qaqish BF 51
Quénel N 283

Rosendahl I 267
Rutqvist L-E 267

Saito Y 163
Saku M 221
Salomon DS 293
Salzano F 147
Sánchez-Jiménez F 187
Santangelo M 243
Sartorius O 255
Sasa M 157
Savitz D 79
Smith J 23
Smith K 293
Sorensen M 39
Sugimachi K 221

Tachovsky T 211
Tagliabue E 195
Takanaka T 163
Tanaka K 157
Taniya T 163
Tortoriello A 243
Trojani M 283
Tucker S 211

Uyama T 157

Vann D 61
Viadro CI 7

Wafflart J 283
Wen D 293
Westermann C 277
Williams L 277
Wolf DM 233

Yokoyama K 163
Yu H 115

Breast Cancer Research and Treatment **35**: 301-304, 1995.
© 1995 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 35

4-hydroxyandrostenedione
response after aminoglutethimide 249-253

accessory breast tissue
bilateral axillary mastopathy in advanced breast cancer — case 221-224
adipose tissue
omega-3 and omega-6 fatty acid content (= consumption) not related to risk 91-95
aminoglutethimide
4-OH androstenedione response after AG failure 249-253
amphiregulin
expression of amphiregulin, heregulin, and cripto-1 mRNAs 293-297
antiestrogen resistance
and molecular variants of the estrogen receptor 233-241
apocrine cysts
fluid Na/K and creatinine analysis for classification 255-266
aromatase inhibitors
4-OH androstenedione response after aminogluthethimide 249-253
axillary mastopathy
bilateral, in advance breast cancer — case 221-224

basement membrane
see laminin and laminin receptor
black women
see minority women
bone marrow support
high-dose epirubicin with lonidamine and α-interferon 243-248
high-dose mitoxantrone plus vinorelbine with G-CSF 147-156
breast cancer etiology
Carolina Breast Cancer Study of traditional, environmental, and genetic risk factors 51-60
breast cancer progression
epidemiologic studies, carcinoma in-situ 65-77
breast cancer team
integration of psychosocial counselor 39-42
breast cysts
fluid Na/K and creatinine analysis for cyst classification 255-266
Breast Cancer Prevention Trial
analysis of accrual by CCOP members 43-50
breast-conserving surgery
survival and cosmetic outcome of wide excision with latissimus dorsi transposition 163-171

cancer registries
use in rapid reporting of cases for risk factor study 61-64
carcinogen-metabolizing enzymes
polymorphisms in studies of gene-environment risk factor interactions 79-89
carcinoma in-situ
background and advantages in breast epidemiologic studies 65-77
cathepsin D
altered level and isoform profile in normal vs. malignant breast cells 211-220
chemoprevention
analysis of CCOP accrual to the Breast Cancer Prevention Trial 43-50
chemotherapy
high-dose epirubicin with lonidamine and α-interferon 243-248
high-dose mitoxantrone plus vinorelbine with G-CSF 147-156
chlorpheniramine
inhibition of ornithine decarboxylase and breast cancer cell growth 187-194
community intervention
lay health advisors in reaching older, minority, rural women 23-29
North Carolina model for reaching older minority women 7-22

Community Clinical Oncology Program (CCOP)
analysis of accrual to the Breast Cancer Prevention Trial 43-50
cosmesis
survival and cosmetic outcome of wide excision with LDM transposition 163-171
creatinine
in cyst fluid analysis for cyst classification 255-266
cripto-1
expression of amphiregulin, heregulin, and cripto-1 mRNAs 293-297
cyst fluids
Na/K and creatinine analysis for cyst classification 255-266
cysts
progression, apocrine to attenuated 255-266

DCIS
see carcinoma in-situ
diet
omega-3 and omega-6 fatty acid consumption not related to risk 91-95
digital mammography
and MRI for screening dense breasts 31-38
duct secretions
Na/K and creatinine analysis for cyst classification 255-266

EGF family
expression of amphiregulin, heregulin, and cripto-1 mRNAs 293-297
EGF receptor family
heterodimerization and functional interaction of EGFR family members 115-132
endocrine therapy
4-OH androstenedione response after aminogluthethimide 249-253
molecular ER variants and antiestrogen resistance 233-241
environment-gene interactions
see gene-environment interactions
environmental exposures
and breast cancer risk 79-89
epidemiology
carcinoma in-situ in etiologic studies 65-77
see also molecular epidemiology
epidermal growth factor
see EGF
epirubicin
high-dose, with lonidamine and α-interferon 243-248
*erb*B-2
see HER-2
estrogen receptor
inverse correlation with HER-2 201-210
molecular variants and antiestrogen resistance 233-241

fatty acids
omega-3 and omega-6 fatty acid consumption not related to risk 91-95
fish oil
omega-3 and omega-6 fatty acid consumption not related to risk 91-95
focal adhesion kinase
in review of protein kinases in human breast cancer 105-114

gene amplification
association with rare Ha-*ras* alleles and breast cancer susceptibility 97-104
gene-environment interactions
Carolina Breast Cancer Study of traditional, environmental, and genetic risk factors 51-60
polymorphisms in carcinogen-metabolizing enzymes 79-89
genetic susceptibility
Carolina risk factor study 51-60
genomic instability
marked by rare Ha-*ras* alleles? 97-104

health education
"natural helpers" as lay health advisors in community outreach 23-29
HER-2 / c-*erb*B-2
in review of protein kinases in human breast cancer 105-114
inverse correlation with ER and PgR 201-210
prognostic value in 942 cases 283-291
HER-2, HER-3, HER-4
heterodimerization and functional interaction of EGF receptor family members 115-132
heregulin
expression of amphiregulin, heregulin, and cripto-1 mRNAs 293-297

heterodimerization
and functional interaction of EGF receptor family members 115-132
high-dose chemotherapy
see bone marrow support

imaging
digital mammography and magnetic resonance imaging for dense breasts 31-38
interferon
high-dose epirubicin with lonidamine and α-interferon 243-248

laminin and laminin receptor
as prognostic factors 195-199
latissimus dorsi transposition
survival and cosmetic outcome of wide excision with LDM transposition 163-171
lay health advisors
in community outreach 23-29
LCIS
see carcinoma in-situ

magnetic resonance imaging (MRI)
and digital mammography for screening dense breasts 31-38
mammography
digital mammography and magnetic resonance imaging for dense breasts 31-38
North Carolina model for reaching older, minority, rural women 7-22
marrow support
see bone marrow support
medroxyprogesterone acetate (MPA)
direct stimulation of primary cultures through PgR 173-186
minority women
"natural helpers" as lay health advisors in community outreach 23-29
North Carolina model for reaching older, minority, rural women 7-22
mitoxantrone
high-dose with vinorelbine, G-CSF support 147-156
molecular epidemiology
cancer registries in rapid case reporting 61-64
Carolina Breast Cancer Study of traditional, environmental, and genetic risk factors 51-60
molecular epidemiology (cont.)
North Carolina SPORE overview 1-5

"natural helpers"
in North Carolina model for reaching older, minority, rural women 23-29
nipple aspirates
Na/K and creatinine analysis for cyst classification 255-266
nodal metastasis
thymidylate synthetase in positive nodes vs. primary tumors 157-162
North Carolina Breast Cancer Screening Program
model for reaching older, minority, rural women 7-22
North Carolina SPORE
overview 1-5
special issue 1-144
novel genes
methods for discovery in breast cancer 105-114

occupation exposures
in studies of risk factors 79-89
oncogenes
see ras, HER-2
oncology clinics
integration of psychosocial counselor 39-42
ornithine decarboxylase
and breast cancer cell growth, chlorpheniramine inhibition 187-194
oxytocin
role in breast cancer prevention — hypothesis 225-229

panel data analysis
analysis of CCOP accrual to the Breast Cancer Prevention Trial 43-50
patient management
integration of psychosocial counselor 39-42
pesticides
in studies of risk factors 79-89
phosphotyrosine
by immunohistochemistry, as a prognostic factor 277-282
polyamines
chlorpheniramine inhibition of ornithine decarboxylase and breast cancer cell growth 187-194

population-based studies
cancer registries in rapid reporting of cases 61-64
Carolina Breast Cancer Study of traditional, environmental, and genetic risk factors 51-60
of environmental exposures and breast cancer risk 79-89
precursor lesions
epidemiologic studies, carcinoma in-situ 65-77
prevention
possible role of oxytocin via nipple stimulation — hypothesis 225-229
progesterone receptor
in stimulation of primary cultures by MPA 173-186
inverse correlation with HER-2 201-210
progestins
direct stimulation of primary cultures by MPA through PgR 173-186
prognostic factors
HER-2/c-*erb*B-2 in 942 cases 283-291
HER-2, inverse correlation with ER and PgR 201-210
laminin and laminin receptor 195-199
phosphotyrosine content by immunohistochemistry 277-282
proteases
see cathepsins
protein kinases
in human breast cancer — review 105-114
psychosocial care
integration into regular oncology clinic contacts 39-42
public health interventions
North Carolina SPORE overview 1-5

race
see minority women
ras oncogene
and Ras-related proteins — aberrant functions in human breast cancer 133-144
rare alleles in breast cancer susceptibility 97-104
risk factors
Carolina Breast Cancer Study of traditional, environmental, and genetic factors 51-60
environmental exposures 79-89
risk factors (cont.)
omega-3 and omega-6 fatty acid consumption not related to risk 91-95
rare Ha-*ras* alleles, genomic instability, and risk 97-104

screening
breast cancer survival in non-attenders (Stockholm trial) 267-275
digital mammography and magnetic resonance imaging for dense breasts 31-38
North Carolina model for reaching older, minority, rural women 7-22
reasons for non-attendance (Stockholm trial) 267-275
signal transduction pathways
aberrant *ras* function in human breast cancer 133-144
see also tyrosine kinases
SPORE special issue
University of North Carolina 1-144
surgery
bilateral axillary mastopathy of accessory breast in advanced breast cancer — case 221-224
see also breast-conserving surgery

tamoxifen resistance
and molecular variants of the estrogen receptor 233-241
thymidylate synthetase
in positive nodes vs. primary tumors 157-162
tumor progression
thymidylate synthetase in positive nodes vs. primary tumors 157-162
tyrosine kinases
heterodimerization and functional interaction of EGF receptor family members 115-132
in human breast cancer — review 105-114
tumor phosphotyrosine content as a prognostic factor 277-282

vinorelbine
high-dose with mitoxantrone, G-CSF support 147-156
VNTRs (variable number tandem repeats)
rare Ha-*ras* alleles and breast cancer susceptibility 97-104